INTERNATIONAL PATENT: DAEWOONG CO., LTD., 주식회사 대웅 FILES APPLICATION FOR "FUSION PROTEIN FUSED WITH IGG FC DOMAIN AND COMPRISING LRRD2 OF SLIT3 PROTEIN AND USE THEREOF FOR IMPROVING MUSCLE FUNCTION, ENHANCING MUSCLE STRENGTH, OR PREVENTING OR TREATING MUSCLE DISEASE"

GENEVA, Jan. 13 -- DAEWOONG CO., LTD. (244, Galmachi-ro, Jungwon-guSeongnam-siGyeonggi-do 13211), 주식회사 대웅 (경기도성남시중원구 갈마치로 244) filed a patent application (PCT/KR2025/009694) for "FUSION PROTEIN FUSED WITH IGG FC DOMAIN AND COMPRISING LRRD2 OF SLIT3 PROTEIN, AND USE THEREOF FOR IMPROVING MUSCLE FUNCTION, ENHANCING MUSCLE STRENGTH, OR PREVENTING OR TREATING MUSCLE DISEASE" on Jul 07, 2025. With publication no. WO/2026/010461, the details related to the patent application was published on Jan 08, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which...